NCT00470145View on ClinicalTrials.gov

Comparison Of Two Tablet Formulations Of SB-568859

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 30, 2007

Study Completion Date

July 31, 2007

Conditions
Atherosclerosis
Interventions
DRUG

SB-568859

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY